search
Back to results

S-531011 as Monotherapy and in Combination With an Immune Checkpoint Inhibitor in Advanced or Metastatic Solid Tumors (aCCeleR8-001)

Primary Purpose

Solid Tumors

Status
Recruiting
Phase
Phase 1
Locations
International
Study Type
Interventional
Intervention
S-531011
Pembrolizumab
Sponsored by
Shionogi
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Solid Tumors focused on measuring C-C motif chemokine receptor 8 (CCR8)

Eligibility Criteria

18 Years - undefined (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  1. Male or female participant must be at least 18 years of age inclusive (or complies with country-specific regulatory requirements, at least 20 years of age in Japan), at the time of signing the informed consent.
  2. Participants with histologically or cytologically confirmed advanced (locoregionally recurrent, not amenable to curative therapy) or metastatic solid tumors who have no standard therapies with a proven clinical benefit, or who are intolerant to or unwilling to receive these therapies for any reasons.
  3. Measurable disease by RECIST 1.1.
  4. (Part A only) Participants should have 1 of the following tumor types: malignant melanoma (MEL), head and neck squamous cell carcinoma (HNSCC), renal cell carcinoma (RCC), urothelial carcinoma (UC), non-small cell lung cancer (NSCLC), or triple-negative breast cancer (TNBC), esophageal cancer (EC; esophageal squamous cell carcinoma and adenocarcinoma), or gastric cancer (GC; gastric and gastroesophageal junction adenocarcinoma).
  5. (Part B only) Participants should have 1 of specific histologically or cytologically confirmed tumor types selected by the sponsor after completion of Part A-1.
  6. (Part C only) Participants should have 1 of specific histologically or cytologically confirmed tumor types selected by the sponsor after completion of Part A-2.
  7. Participants should be willing and able to provide permission to access archival formalin-fixed paraffin-embedded (FFPE) tumor tissues (as block or unstained slides) for this study.
  8. Participants should be willing and able to provide both pre-treatment and on-treatment paired tumor biopsy samples.
  9. (At selected sites only) Participants should be willing and able to provide both pre-treatment and on-treatment paired tumor biopsy samples. Fresh tissue samples are required as these will be used for the proof of mechanism analysis.
  10. Eastern Cooperative Oncology Group Performance Status (ECOG PS) of 0 or 1.
  11. An estimated life expectancy of at least 12 weeks.
  12. Adequate hematologic and organ function as confirmed by laboratory values.
  13. QT interval corrected with the Fridericia formula (QTcF) ≤ 480 milliseconds in 12-lead electrocardiogram (ECG) at Screening.

Exclusion Criteria:

  1. Presence or history of autoimmune diseases or immune-mediated diseases that require chronic use of systemic corticosteroids (> 10 mg of prednisone equivalent per day), immunosuppressive agents, or disease-modifying agents.
  2. Active clinically significant bacterial, viral or fungal infection, or any major episode of infection requiring hospitalization or treatment with parenteral antiinfectives within 4 weeks before the first dose of study intervention.
  3. Uncontrolled or clinically significant cardiovascular disease defined as New York Heart Association (NYHA) classification III or IV.
  4. A positive test for hepatitis B surface antigen (HBsAg) and/or hepatitis C virus (HCV) antibody (a confirmatory HCV RNA test if HCV antibody was positive).
  5. A positive serological test for human immunodeficiency virus (HIV) infection.
  6. Known history of any other relevant congenital or acquired immunodeficiency.
  7. Known history of severe allergy, hypersensitivity, anaphylaxis, or any serious adverse reaction to any component of study intervention or formulation components and/or any other monoclonal antibodies.
  8. Women who are pregnant or breastfeeding or trying to become pregnant.
  9. Clinical evidence of uncontrolled brain metastasis.
  10. Clinical evidence of any active second invasive malignancy (except stable prostate cancer on watchful waiting).
  11. (Parts A-2 and C only): Participants who developed an immune-related adverse event (irAE) during prior pembrolizumab treatment that required a delay in the scheduled administration for more than 4 weeks due to any grade of irAEs or led to permanent discontinuation of pembrolizumab. Also, participants whose previous irAE due to pembrolizumab has not resolved to ≤ Grade 1 and/or still requires corticosteroids (> 10 mg of prednisone-equivalent per day).
  12. Prior treatment with systemic anticancer drugs (including any investigational medicinal products) within 28 days or 5 half-lives (whichever is shorter) before the first dose of study intervention.
  13. Prior major surgery within 28 days before the first dose of study intervention.
  14. Prior extended field radiotherapy within 28 days before the first dose of study intervention (within 14 days for limited field radiation for palliation).
  15. Participants who have not recovered from any previous treatment toxicities to ≤ Grade 1 or baseline (except alopecia and peripheral neuropathy) before the first dose of study intervention.
  16. Prior treatment with anti-CCR8 antibody for any indication.
  17. Receipt of a live, attenuated vaccine within 28 days before the first dose of study intervention.

Sites / Locations

  • Angeles Clinic and Research CenterRecruiting
  • Henry Ford Health CenterRecruiting
  • Fox Chase Cancer CenterRecruiting
  • National Cancer Center Hospital EastRecruiting
  • Osaka University HospitalRecruiting
  • National Cancer Center HospitalRecruiting

Arms of the Study

Arm 1

Arm 2

Arm 3

Arm 4

Arm Type

Experimental

Experimental

Experimental

Experimental

Arm Label

Part A-1: S-531011 Monotherapy

Part A-2: S-531011 + Pembrolizumab

Part B: S-531011 Monotherapy

Part C: S-531011 + Pembrolizumab

Arm Description

Participants will receive escalating doses of S-531011 by intravenous infusion for up to approximately 12 months.

Participants will receive escalating doses of S-531011 in combination with pembrolizumab by intravenous infusion for up to approximately 12 months.

Participants will receive S-531011 at the the RP2D by intravenous infusion for up to approximately 12 months.

Participants will receive S-531011 at the RP2D in combination with pembrolizumab by intravenous infusion for up to approximately 12 months.

Outcomes

Primary Outcome Measures

Part A: Number of Participants with Treatment-emergent Adverse Events (TEAEs)
Parts B and C: Objective Response Rate
Parts B and C: Duration of Response
Parts B and C: Disease Control Rate
Parts B and C: Time to Response
Parts B and C: Progression-free Survival
Parts B and C: Overall Survival

Secondary Outcome Measures

Part A: Objective Response Rate
Part A: Duration of Response
Part A: Disease Control Rate
Part A: Time to Response
Part A: Progression-free Survival
All Parts: Serum concentrations of S-531011
Part A: Maximum Serum Concentration (Cmax) of S-531011
Part A: Time to Maximum Serum Concentration (Tmax) of S-531011
Part A: Area Under the Concentration-time Curve from Time Zero to the Time of Last Quantifiable Concentration After Dosing (AUC0-last) of S-531011
Part A: Area Under the Concentration-time Curve Extrapolated from Time Zero to Infinity (AUCinf) of S-531011
Part A: Terminal elimination rate constant (λz) of S-531011
Part A: Terminal Elimination Half-life (t1/2,z) of S-531011
Part A: Total Clearance (CL) of S-531011
Part A: Volume of Distribution at Steady State (Vss) of S-531011
Part A: Mean Residence Time (MRT) of S-531011
All Parts: Anti-S-531011 Antibody (ADA) Titer Level
All Parts: Changes in serum tumor markers from pretreatment to on-treatment
Part B and C: Number of Participants with Treatment-emergent Adverse Events (TEAEs)

Full Information

First Posted
October 14, 2021
Last Updated
September 28, 2023
Sponsor
Shionogi
Collaborators
Merck Sharp & Dohme LLC
search

1. Study Identification

Unique Protocol Identification Number
NCT05101070
Brief Title
S-531011 as Monotherapy and in Combination With an Immune Checkpoint Inhibitor in Advanced or Metastatic Solid Tumors
Acronym
aCCeleR8-001
Official Title
A Phase 1b/2, Multicenter, Open-label Study of S-531011 as Monotherapy and in Combination With an Immune Checkpoint Inhibitor in Participants With Locally Advanced or Metastatic Solid Tumors
Study Type
Interventional

2. Study Status

Record Verification Date
September 2023
Overall Recruitment Status
Recruiting
Study Start Date
May 30, 2022 (Actual)
Primary Completion Date
April 16, 2027 (Anticipated)
Study Completion Date
April 16, 2027 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Shionogi
Collaborators
Merck Sharp & Dohme LLC

4. Oversight

Studies a U.S. FDA-regulated Drug Product
Yes
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
Yes

5. Study Description

Brief Summary
The primary objective of Part A is to evaluate the safety and tolerability of S-531011 and to determine the maximum tolerated dose (MTD) and/or recommended Phase 2 dose (RP2D) of S-531011. The primary objective of Parts B and C is to evaluate the antitumor activity of S-531011 at the RP2D.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Solid Tumors
Keywords
C-C motif chemokine receptor 8 (CCR8)

7. Study Design

Primary Purpose
Treatment
Study Phase
Phase 1, Phase 2
Interventional Study Model
Sequential Assignment
Masking
None (Open Label)
Allocation
Non-Randomized
Enrollment
274 (Anticipated)

8. Arms, Groups, and Interventions

Arm Title
Part A-1: S-531011 Monotherapy
Arm Type
Experimental
Arm Description
Participants will receive escalating doses of S-531011 by intravenous infusion for up to approximately 12 months.
Arm Title
Part A-2: S-531011 + Pembrolizumab
Arm Type
Experimental
Arm Description
Participants will receive escalating doses of S-531011 in combination with pembrolizumab by intravenous infusion for up to approximately 12 months.
Arm Title
Part B: S-531011 Monotherapy
Arm Type
Experimental
Arm Description
Participants will receive S-531011 at the the RP2D by intravenous infusion for up to approximately 12 months.
Arm Title
Part C: S-531011 + Pembrolizumab
Arm Type
Experimental
Arm Description
Participants will receive S-531011 at the RP2D in combination with pembrolizumab by intravenous infusion for up to approximately 12 months.
Intervention Type
Drug
Intervention Name(s)
S-531011
Intervention Description
Administered by intravenous infusion
Intervention Type
Drug
Intervention Name(s)
Pembrolizumab
Other Intervention Name(s)
Keytruda®
Intervention Description
Administered by intravenous infusion
Primary Outcome Measure Information:
Title
Part A: Number of Participants with Treatment-emergent Adverse Events (TEAEs)
Time Frame
Approximately 12 months
Title
Parts B and C: Objective Response Rate
Time Frame
Every 6 weeks for the first 24 weeks and every 9 weeks thereafter, until the end of treatment (approximately 12 months).
Title
Parts B and C: Duration of Response
Time Frame
From first dose up to a maximum of 18 months after last dose; 2.5 years
Title
Parts B and C: Disease Control Rate
Time Frame
Every 6 weeks for the first 24 weeks and every 9 weeks thereafter, until the end of treatment (approximately 12 months).
Title
Parts B and C: Time to Response
Time Frame
Every 6 weeks for the first 24 weeks and every 9 weeks thereafter, until the end of treatment (approximately 12 months).
Title
Parts B and C: Progression-free Survival
Time Frame
From first dose up to a maximum of 18 months after last dose; 2.5 years
Title
Parts B and C: Overall Survival
Time Frame
From first dose up to a maximum of 18 months after last dose; 2.5 years
Secondary Outcome Measure Information:
Title
Part A: Objective Response Rate
Time Frame
Every 6 weeks for the first 24 weeks and every 9 weeks thereafter, until the end of treatment (approximately 12 months).
Title
Part A: Duration of Response
Time Frame
From first dose up to a maximum of 18 months after last dose; 2.5 years
Title
Part A: Disease Control Rate
Time Frame
Every 6 weeks for the first 24 weeks and every 9 weeks thereafter, until the end of treatment (approximately 12 months).
Title
Part A: Time to Response
Time Frame
Every 6 weeks for the first 24 weeks and every 9 weeks thereafter, until the end of treatment (approximately 12 months).
Title
Part A: Progression-free Survival
Time Frame
From first dose up to a maximum of 18 months after last dose; 2.5 years
Title
All Parts: Serum concentrations of S-531011
Time Frame
Cycle 1, Day 1: pre-infusion, end-of-infusion, and 1 and 3 hours after the end-of S-531011 infusion, and 24, 48, 72 hours after the start of S-531011 infusion (each cycle is 21 days).
Title
Part A: Maximum Serum Concentration (Cmax) of S-531011
Time Frame
Cycle 1, Day 1: pre-infusion, end-of-infusion, and 1 and 3 hours after the end-of S-531011 infusion, and 24, 48, 72 hours after the start of S-531011 infusion (each cycle is 21 days).
Title
Part A: Time to Maximum Serum Concentration (Tmax) of S-531011
Time Frame
Cycle 1, Day 1: pre-infusion, end-of-infusion, and 1 and 3 hours after the end-of S-531011 infusion, and 24, 48, 72 hours after the start of S-531011 infusion (each cycle is 21 days).
Title
Part A: Area Under the Concentration-time Curve from Time Zero to the Time of Last Quantifiable Concentration After Dosing (AUC0-last) of S-531011
Time Frame
Cycle 1, Day 1: pre-infusion, end-of-infusion, and 1 and 3 hours after the end-of S-531011 infusion, and 24, 48, 72 hours after the start of S-531011 infusion (each cycle is 21 days).
Title
Part A: Area Under the Concentration-time Curve Extrapolated from Time Zero to Infinity (AUCinf) of S-531011
Time Frame
Cycle 1, Day 1: pre-infusion, end-of-infusion, and 1 and 3 hours after the end-of S-531011 infusion, and 24, 48, 72 hours after the start of S-531011 infusion (each cycle is 21 days).
Title
Part A: Terminal elimination rate constant (λz) of S-531011
Time Frame
Cycle 1, Day 1: pre-infusion, end-of-infusion, and 1 and 3 hours after the end-of S-531011 infusion, and 24, 48, 72 hours after the start of S-531011 infusion (each cycle is 21 days).
Title
Part A: Terminal Elimination Half-life (t1/2,z) of S-531011
Time Frame
Cycle 1, Day 1: pre-infusion, end-of-infusion, and 1 and 3 hours after the end-of S-531011 infusion, and 24, 48, 72 hours after the start of S-531011 infusion (each cycle is 21 days).
Title
Part A: Total Clearance (CL) of S-531011
Time Frame
Cycle 1, Day 1: pre-infusion, end-of-infusion, and 1 and 3 hours after the end-of S-531011 infusion, and 24, 48, 72 hours after the start of S-531011 infusion (each cycle is 21 days).
Title
Part A: Volume of Distribution at Steady State (Vss) of S-531011
Time Frame
Cycle 1, Day 1: pre-infusion, end-of-infusion, and 1 and 3 hours after the end-of S-531011 infusion, and 24, 48, 72 hours after the start of S-531011 infusion (each cycle is 21 days).
Title
Part A: Mean Residence Time (MRT) of S-531011
Time Frame
Cycle 1, Day 1: pre-infusion, end-of-infusion, and 1 and 3 hours after the end-of S-531011 infusion, and 24, 48, 72 hours after the start of S-531011 infusion (each cycle is 21 days).
Title
All Parts: Anti-S-531011 Antibody (ADA) Titer Level
Time Frame
Day 1 of Cycles 1 to 9 (each cycle is 21 days)
Title
All Parts: Changes in serum tumor markers from pretreatment to on-treatment
Time Frame
Baseline and Day 1 of each treatment cycle (each cycle is 21 days)
Title
Part B and C: Number of Participants with Treatment-emergent Adverse Events (TEAEs)
Time Frame
Approximately 12 months

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Male or female participant must be at least 18 years of age inclusive (or complies with country-specific regulatory requirements), at the time of signing the informed consent. Participants with histologically or cytologically confirmed advanced (locoregionally recurrent, not amenable to curative therapy) or metastatic solid tumors who have no standard therapies with a proven clinical benefit, or who are intolerant to or unwilling to receive these therapies for any reasons. Measurable disease by RECIST 1.1. (Part A only) Participants should have 1 of the following tumor types: malignant melanoma (MEL), head and neck squamous cell carcinoma (HNSCC), renal cell carcinoma (RCC), urothelial carcinoma (UC), non-small cell lung cancer (NSCLC), or triple-negative breast cancer (TNBC), esophageal cancer (EC; esophageal squamous cell carcinoma and adenocarcinoma), or gastric cancer (GC; gastric and gastroesophageal junction adenocarcinoma). (Part B only) Participants should have 1 of specific histologically or cytologically confirmed tumor types selected by the sponsor after the determination of tentative RP2D(s) in Part A-1. (Part C only) Participants should have 1 of specific histologically or cytologically confirmed tumor types selected by the sponsor after the determination of tentative RP2D(s) in Part A-2. Participants should be willing and able to provide permission to access archival formalin-fixed paraffin-embedded (FFPE) tumor tissues (as block or unstained slides) for this study. Participants should be willing and able to provide both pre-treatment and on-treatment paired tumor biopsy samples. (At selected sites only) Participants should be willing and able to provide both pre-treatment and on-treatment paired tumor biopsy samples. Fresh tissue samples are required as these will be used for the proof of mechanism analysis. Eastern Cooperative Oncology Group Performance Status (ECOG PS) of 0 or 1. An estimated life expectancy of at least 12 weeks. Adequate hematologic and organ function as confirmed by laboratory values. QT interval corrected with the Fridericia formula (QTcF) ≤ 480 milliseconds in 12-lead electrocardiogram (ECG) at Screening. Exclusion Criteria: Presence or history of autoimmune diseases or immune-mediated diseases that require chronic use of systemic corticosteroids (> 10 mg of prednisone equivalent per day), immunosuppressive agents, or disease-modifying agents. Presence or history of interstitial lung disease and (non-infectious) pneumonitis that required corticosteroids. Active clinically significant bacterial, viral or fungal infection, or any major episode of infection requiring hospitalization or treatment with parenteral anti-infectives within 4 weeks before the first dose of study intervention. Uncontrolled or clinically significant cardiovascular disease defined as New York Heart Association (NYHA) classification III or IV. A positive test for hepatitis B surface antigen (HBsAg) and/or hepatitis C virus (HCV) antibody (a confirmatory HCV RNA test if HCV antibody was positive). A positive serological test for human immunodeficiency virus (HIV) infection. Known history of any other relevant congenital or acquired immunodeficiency. Known history of an allogeneic tissue and/or solid organ transplant. Known history of severe allergy, hypersensitivity, anaphylaxis, or any serious adverse reaction to any component of study intervention or formulation components and/or any other monoclonal antibodies. Women who are pregnant or breastfeeding or trying to become pregnant. Clinical evidence of uncontrolled brain metastasis. Known additional malignancy that is progressing or has required active treatment within the past 3 years. (Parts A-2 and C only): Has received prior therapy with an anti-PD-1, anti-PD-L1, or anti-PD-L2 agent or with an agent directed to another stimulatory or co-inhibitory T-cell receptor (eg, CTLA-4, OX-40, CD137), and was discontinued from that treatment due to ≥ Grade 3 immune-related adverse event (irAE). Prior treatment with systemic anticancer drugs (including any investigational medicinal products) within 28 days or 5 half-lives (whichever is shorter) before the first dose of study intervention. Prior major surgery within 28 days before the first dose of study intervention. Prior extended field radiotherapy within 28 days before the first dose of study intervention (within 14 days for limited field radiation for palliation) or history of radiation pneumonitis. Participants who have not recovered from any previous treatment toxicities to ≤ Grade 1 or baseline (except alopecia and peripheral neuropathy) before the first dose of study intervention. Prior treatment with anti-CCR8 antibody for any indication. Receipt of hematopoietic growth factors (eg, granulocyte-colony stimulating factor [G-CSF] or erythropoietin) within 14 days before the first dose of study intervention or blood transfusions within 14 days before the first dose of study intervention. Receipt of a live, attenuated vaccine within 30 days before the first dose of study intervention.
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Shionogi Clinical Trials Administrator Clinical Support Help Line
Phone
800-849-9707
Email
Shionogiclintrials-admin@shionogi.co.jp
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Shionogi Clinical Trials Administrator Clinical Support Help Line
Organizational Affiliation
Shionogi
Official's Role
Study Director
Facility Information:
Facility Name
Angeles Clinic and Research Center
City
Los Angeles
State/Province
California
ZIP/Postal Code
90025
Country
United States
Individual Site Status
Recruiting
Facility Name
Henry Ford Health Center
City
Detroit
State/Province
Michigan
ZIP/Postal Code
48202
Country
United States
Individual Site Status
Recruiting
Facility Name
Fox Chase Cancer Center
City
Philadelphia
State/Province
Pennsylvania
ZIP/Postal Code
19111
Country
United States
Individual Site Status
Recruiting
Facility Name
National Cancer Center Hospital East
City
Kashiwa
State/Province
Chiba
Country
Japan
Individual Site Status
Recruiting
Facility Name
Osaka University Hospital
City
Suita
State/Province
Osaka
Country
Japan
Individual Site Status
Recruiting
Facility Name
National Cancer Center Hospital
City
Chuo Ku
State/Province
Tokyo
Country
Japan
Individual Site Status
Recruiting

12. IPD Sharing Statement

Learn more about this trial

S-531011 as Monotherapy and in Combination With an Immune Checkpoint Inhibitor in Advanced or Metastatic Solid Tumors

We'll reach out to this number within 24 hrs